All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
ASH 2019 | Practice-changing abstracts in lymphoma and CLL
Bookmark this article
Did you miss ASH 2019? The Lymphoma Hub attended the 61st ASH Annual Meeting & Exposition, December 7-10 2019, Orlando, US, and has developed a downloadable resource on the practice-changing abstracts in lymphoma and CLL.
In this resource, you will find comments from the Lymphoma Hub Steering Committee members on DLBCL prognostic factors, MCL novel treatment options, FL chemo-free treatment options, treating patients with newly diagnosed CLL, R/R CLL, and poor-prognosis NHL, and the role of maintenance therapy in Waldenstrӧm’s macroglobulinemia.
Updated November 24, 2020.
ASH 2019 | Practice-changing abstracts in lymphoma and CLL
If you would like to view the practice-changing abstracts from ASH 2019 and the expert opinions from our Steering Committee, please download the resource below.
Download HereMore about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 46 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox